Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
15 hedge funds and large institutions have $1.04M invested in Better Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
12% less funds holding
Funds holding: 17 → 15 (-2)
40% less capital invested
Capital invested by funds: $1.75M → $1.04M (-$704K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$17.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$4.4K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.35K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.1K |
| 5 |
BlackRock
New York
|
+$937 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$135K |
| 2 |
Two Sigma Investments
New York
|
-$13.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.6K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$6.42K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$20 |
BTTX Hedge Fund Activity: Q1 2023 in Review
15 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q1 2023, worth a combined $1.04M — down 40% from $1.75M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BTTX and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Millennium Management, adding an estimated $17.5K. The largest seller was Farallon Capital Management, cutting an estimated $135K.
- 15 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q1 2023, down from 17 in Q4 2022.
- Funds reported $1.04M of Better Therapeutics, Inc. Common Stock stock for Q1 2023, down 40% quarter-over-quarter.
- 0 funds opened new Better Therapeutics, Inc. Common Stock positions in Q1 2023 and 2 closed out, a net change of -2 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q1 2023 was Millennium Management, an estimated $17.5K added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q1 2023 was Farallon Capital Management, an estimated $135K sold.
Based on aggregated 13F filings for Q1 2023.